NCT02744820View on ClinicalTrials.gov

Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
HealthyType 2 Diabetes Mellitus
Interventions
DRUG

GMC-252-L-Lysine Salt

1 dose by oral route, once a day, 28 days

OTHER

Placebo

Matching doses by oral route, once a day, 28 days

Trial Locations (2)

BT2 7BA

BioKinetic Europe Ltd., Belfast

CF48 4DR

Simbec Research Ltd, Merthyr Tydfil

Sponsors
All Listed Sponsors
collaborator

Simbec Research

INDUSTRY

lead

Genmedica Therapeutics S.L.

INDUSTRY

NCT02744820 - Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics | Biotech Hunter | Biotech Hunter